Cargando…

Efficacy and safety of the recombinant zoster vaccine: A systematic review and meta-analysis

In this systematic review with meta-analysis, the efficacy, effectiveness, and safety of the new GSK recombinant zoster vaccine (RZV) were assessed. Twenty three publications reporting on 14 studies were selected, including 2 pivotal RCTs in older immunocompetent adults (ZOE-50 and ZOE-70), 4 RCTs o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeevaert, Renate, Thiry, Nancy, Maertens de Noordhout, Charline, Roberfroid, Dominique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589374/ https://www.ncbi.nlm.nih.gov/pubmed/37867572 http://dx.doi.org/10.1016/j.jvacx.2023.100397

Ejemplares similares

Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals
por: Curran, Desmond, et al.
Publicado: (2020)

Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence
por: Parikh, Raunak, et al.
Publicado: (2023)

A Broad Safety Assessment of the Recombinant Herpes Zoster Vaccine
por: Yih, W Katherine, et al.
Publicado: (2022)

Preventing Varicella-Zoster: Advances With the Recombinant Zoster Vaccine
por: Ilyas, Sahrish, et al.
Publicado: (2020)

Efficacy and safety of bloodletting for herpes zoster: A protocol for systematic review and meta-analysis
por: Wang, Xiaoyan, et al.
Publicado: (2021)

Herpes Zoster Following Recombinant Zoster Vaccine With or Without Concomitant Vaccination
por: Bruxvoort, Katia J, et al.
Publicado: (2022)

Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis
por: Tricco, Andrea C, et al.
Publicado: (2018)

Efficacy, effectiveness, and safety of herpes zoster vaccine in the immunocompetent and immunocompromised subjects: A systematic review and network meta-analysis
por: Xia, Yue, et al.
Publicado: (2022)

Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
por: Tavares-Da-Silva, Fernanda, et al.
Publicado: (2020)

Efficacy and Safety of Electroacupuncture for Pain Control in Herpes Zoster: A Systematic Review and Meta-Analysis
por: He, Kelin, et al.
Publicado: (2022)

Prevention of shingles: safety and efficacy of live zoster vaccine
por: Quan, Dianna, et al.
Publicado: (2007)

Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination
por: Strezova, Ana, et al.
Publicado: (2022)

Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review
por: Giannelos, Nikolaos, et al.
Publicado: (2023)

Efficacy and safety of acupuncture and moxibustion for herpes zoster: A protocol for systematic review and network meta analysis
por: Zhang, Na, et al.
Publicado: (2020)

Healthy ageing: Herpes zoster infection and the role of the adjuvanted recombinant zoster vaccine
por: Curran, D, et al.
Publicado: (2022)

Uveitis reactivation following recombinant zoster vaccination
por: Richards, Paige J., et al.
Publicado: (2021)

Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials
por: López-Fauqued, Marta, et al.
Publicado: (2021)

Systematic Review and Meta-analysis of Herpes Zoster Vaccine in Patients With CKD
por: Hamad, Mohamad A., et al.
Publicado: (2021)

Efficacy and Safety of Pulsed Radiofrequency in Herpes Zoster Related Trigeminal Neuralgia: A Systematic Review and Meta-Analysis
por: Wang, Chenhui, et al.
Publicado: (2023)

114. Long-term Protection Against Herpes Zoster (HZ) by the Adjuvanted Recombinant Zoster Vaccine (RZV): Interim Efficacy, Immuno and Safety Results at Approximately 10 Years after Initial Vaccination
por: Strezova, Ana, et al.
Publicado: (2022)

2776. Post-marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Review of Spontaneous Reports Since Introduction
por: Tavares-Da-Silva, Fernanda, et al.
Publicado: (2019)

Estimated Public Health Impact of the Recombinant Zoster Vaccine
por: Patterson, Brandon J., et al.
Publicado: (2021)

Correction to: 114. Long-term Protection Against Herpes Zoster (HZ) by the Adjuvanted Recombinant Zoster Vaccine (RZV): Interim Efficacy, Immuno and Safety Results at Approximately 10 Years after Initial Vaccination
Publicado: (2023)

Active Postlicensure Safety Surveillance for Recombinant Zoster Vaccine Using Electronic Health Record Data
por: Nelson, Jennifer C, et al.
Publicado: (2022)

Herpes Zoster and Immunogenicity and Safety of Zoster Vaccines in Transplant Patients: A Narrative Review of the Literature
por: Wang, Lei, et al.
Publicado: (2018)

20. Cost-Effectiveness of Recombinant Zoster Vaccine for Vaccinating Immunocompromised Adults Against Herpes Zoster in the United States
por: Curran, Desmond, et al.
Publicado: (2021)

Recombinant zoster vaccine (Shingrix(®)): a new option for the prevention of herpes zoster and postherpetic neuralgia
por: Singh, Grisuna, et al.
Publicado: (2020)

Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines
por: Pleyer, Christopher, et al.
Publicado: (2021)

Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies
por: Mwakingwe-Omari, Agnes, et al.
Publicado: (2023)

The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine
por: Dagnew, Alemnew F, et al.
Publicado: (2020)

Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines
por: Marra, Yasmin, et al.
Publicado: (2022)

Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) — United States, October 2017–June 2018
por: Hesse, Elisabeth M., et al.
Publicado: (2019)

36. Safety and Reactogenicity of the Adjuvanted Recombinant Zoster Vaccine after Allogeneic Hematopoietic Stem Cell Transplantation
por: Baumrin, Emily, et al.
Publicado: (2020)

37. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine (RZV) in Immunocompromised Populations: an Overview of 6 Trials
por: Fauqued, Marta Lopez, et al.
Publicado: (2020)

Safety and reactogenicity of the adjuvanted recombinant zoster vaccine: experience from clinical trials and post-marketing surveillance
por: Fiore, Joseph, et al.
Publicado: (2021)

4. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Adults
por: Dagnew, Alemnew F, et al.
Publicado: (2020)

Multidisciplinary model for administration of recombinant Zoster vaccine in fragile patients
por: Martinelli, S, et al.
Publicado: (2023)

Recombinant varicella zoster virus glycoprotein E antigen vaccine for prevention of herpes zoster and postherpetic neuralgia
Publicado: (2021)

Association of herpes zoster with COVID-19 vaccination: A systematic review and meta-analysis
por: Chen, I-Ling, et al.
Publicado: (2023)

Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany
por: Curran, Desmond, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cd2527giruta5vroac4v8t95p1